SEC Form 4 · accession 0001209191-18-019559
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Laliberte
Officer — Sr. VP, Product Development
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $29.33 | Mar 12, 2018 | A | 50,000 | A | — | Mar 11, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1One-fourth of the shares underlying this option vest on March 12, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.